We describe the case of an 81-year-old woman in whom a mass developed in the chest wall over 3 weeks. No previous mass in that area was reported. Physical examination was remarkable only for a 13 cm painless, purplish mass in the anterior chest wall. No masses were palpable in the anatomic breasts, and no lymphadenopathy was evident. Thoracoabdominal computed tomography showed a 3.5 x 7.0 cm necrotic mass; underlying muscle invasion could not be excluded. Wide excision of the tumor and underlying fascia was done, and margins were clear. Pathology showed a metaplastic carcinoma without continuity with either anatomic breast. Adjuvant radiotherapy was initiated because of the tumor's high-grade features. Twenty-six months after resection and adjuvant treatment, the patient continues to be free of disease. Metaplastic carcinoma is an unusual pathologic finding in the anatomic breast. This is the first report of its occurrence in ectopic breast tissue.
Download full-text PDF |
Source |
---|
World J Clin Cases
January 2025
Department of Surgery, National and Kapodistrian University of Athens, Athens 11527, Greece.
Carcinosarcoma (CS), also known as metaplastic breast carcinoma with mesenchymal differentiation, is one of the five distinct subtypes of metaplastic breast cancer. It is considered as a mixed, biphasic neoplasm consisting of a carcinomatous component combined with a malignant nonepithelial element of mesenchymal origin without an intermediate transition zone. Although cellular origin of this neoplasm remains controversial, most researchers declare that neoplastic cells derive from a cellular structure with potential biphasic differentiation.
View Article and Find Full Text PDFAdv Exp Med Biol
January 2025
INSERM, Bergonie Cancer Institute, University of Bordeaux, Bordeaux, France.
The mammary epithelium has an inner luminal layer that contains estrogen receptor (ER)-positive hormone-sensing cells and ER-negative alveolar/secretory cells, and an outer basal layer that contains myoepithelial/stem cells. Most human tumours resemble either hormone-sensing cells or alveolar/secretory cells. The most widely used molecular classification, the Intrinsic classification, assigns hormone-sensing tumours to Luminal A/B and human epidermal growth factor 2-enriched (HER2E)/molecular apocrine (MA)/luminal androgen receptor (LAR)-positive classes, and alveolar/secretory tumours to the Basal-like class.
View Article and Find Full Text PDFActa Oncol
January 2025
Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.
Background And Purpose: We report the incidence, characteristics, and comorbidities of the complete unselected Danish cohort of patients with thymic epitheliums (TETs), which may serve as evidence for guiding treatment, surveillance, and counselling of TET patients.
Patients And Methods: All patients diagnosed with TETs from January 1st, 2015, to December 31st, 2020, were identified using the Danish Pathology Data Registry. Data on patient characteristics, comorbidities, and tumor histology were collected from electronic medical records available for all patients.
Cancers (Basel)
December 2024
Department of Pathology, Turku University Hospital, 20520 Turku, Finland.
(1) Low-grade adenosquamous carcinoma (LGASC) is a rare subtype of metaplastic breast carcinoma (MpBC), accounting for fewer than 0.05% of breast cancer cases. Unlike the typically aggressive nature of MpBCs, LGASC is an indolent tumor with an excellent prognosis.
View Article and Find Full Text PDFAdv Anat Pathol
November 2024
Department of Radiology, School of Medical Sciences, State University of Campinas (Unicamp), Campinas, Brazil.
Horseshoe kidney is a rare congenital anomaly with an unusually higher frequency of neuroendocrine tumors. Symptoms are rare, and, in most of the cases, are incidentally diagnosed. The clinical behavior of these tumors is heterogeneous and can be difficult to predict based on histology alone.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!